Cited by 635Alzheimer's disease research and treatmentsDementia and Cognitive Impairment ResearchNeuroinflammation and Neurodegeneration Mechanisms

The DOI matches its Crossref record; 197 of the 200 references it cites were found in a registry or an index, and 3 are not checked yet.

Amyloid β oligomers in Alzheimer’s disease pathogenesis, treatment, and diagnosis

Open access

Viola, Kirsten L., Klein, William L.·2015·Acta Neuropathologica

DOI 10.1007/s00401-015-1386-3PMC PMC4390393

Open this paper in CoChat — free account

Abstract

Protein aggregation is common to dozens of diseases including prionoses, diabetes, Parkinson's and Alzheimer's. Over the past 15 years, there has been a paradigm shift in understanding the structural basis for these proteinopathies. Precedent for this shift has come from investigation of soluble Aβ oligomers (AβOs), toxins now widely regarded as instigating neuron damage leading to Alzheimer's dementia. Toxic AβOs accumulate in AD brain and constitute long-lived alternatives to the disease-defining Aβ fibrils deposited in amyloid plaques. Key experiments using fibril-free AβO solutions demonstrated that while Aβ is essential for memory loss, the fibrillar Aβ in amyloid deposits is not the agent. The AD-like cellular pathologies induced by AβOs suggest their impact provides a unifying mechanism for AD pathogenesis, explaining why early stage disease is specific for memory and accounting for major facets of AD neuropathology. Alternative ideas for triggering mechanisms are being actively investigated. Some research favors insertion of AβOs into membrane, while other evidence supports ligand-like accumulation at particular synapses. Over a dozen candidate toxin receptors have been proposed. AβO binding triggers a redistribution of critical synaptic proteins and induces hyperactivity in metabotropic and ionotropic glutamate receptors. This leads to Ca(2+) overload and instigates major facets of AD neuropathology, including tau hyperphosphorylation, insulin resistance, oxidative stress, and synapse loss. Because different species of AβOs have been identified, a remaining question is which oligomer is the major pathogenic culprit. The possibility has been raised that more than one species plays a role. Despite some key unknowns, the clinical relevance of AβOs has been established, and new studies are beginning to point to co-morbidities such as diabetes and hypercholesterolemia as etiological factors. Because pathogenic AβOs appear early in the disease, they offer appealing targets for therapeutics and diagnostics. Promising therapeutic strategies include use of CNS insulin signaling enhancers to protect against the presence of toxins and elimination of the toxins through use of highly specific AβO antibodies. An AD-dependent accumulation of AβOs in CSF suggests their potential use as biomarkers and new AβO probes are opening the door to brain imaging. Overall, current evidence indicates that Aβ oligomers provide a substantive molecular basis for the cause, treatment and diagnosis of Alzheimer's disease.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1007/s00401-015-1386-3

Cites

197 of 200 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

1 retracted

RETRACTED ARTICLE: A specific amyloid-β protein assembly in the brain impairs memory
Lesné, S., Koh, M. T., Kotilinek, L., Kayed, R., Glabe, C. G., Yang, A., Gallagher, M., & Ashe, K. H. (2006) · Nature · doi:10.1038/nature04533 · Cited by 2,769
Retracted
Amyloid oligomers exacerbate tau pathology in a mouse model of tauopathy
Selenica, M.-L. B., Brownlow, M., Jimenez, J. P., Lee, D. C., Pena, G., Dickey, C. A., Gordon, M. N., & Morgan, D. (2013) · Neurodegenerative Diseases · doi:10.1159/000337230 · Cited by 10,359
Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound‐B
Klunk, W. E., Engler, H., Nordberg, A., Wang, Y., Blomqvist, G., Holt, D. P., Bergström, M., Savitcheva, I., Huang, G., Estrada, S., et al. (2004) · Annals of Neurology · doi:10.1002/ana.20009 · Cited by 4,496
Naturally secreted oligomers of amyloid β protein potently inhibit hippocampal long-term potentiation in vivo
Walsh, D. M., Klyubin, I., Fadeeva, J. V., Cullen, W. K., Anwyl, R., Wolfe, M. S., Rowan, M. J., & Selkoe, D. J. (2002) · Nature · doi:10.1038/416535a · Cited by 4,291
Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis
Kayed, R., Head, E., Thompson, J. L., McIntire, T. M., Milton, S. C., Cotman, C. W., & Glabe, C. G. (2003) · Science · doi:10.1126/science.1079469 · Cited by 4,064
Diffusible, nonfibrillar ligands derived from Aβ 1–42 are potent central nervous system neurotoxins
Lambert, M. P., Barlow, A. K., Chromy, B. A., Edwards, C., Freed, R., Liosatos, M., Morgan, T. E., Rozovsky, I., Trommer, B., Viola, K. L., et al. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.11.6448 · Cited by 3,506
Self-citation
Journal of Biological Chemistry
Kurkinensp, M., CondongT, M. R., Blumberg, B., Barlow, D. P., Quiñones, S., Sausg, J., & Pihlajaniemisyy, T. (2021) · Journal of Biological Chemistry · doi:10.1074/jbc · Cited by 3,427
Curcumin Inhibits Formation of Amyloid β Oligomers and Fibrils, Binds Plaques, and Reduces Amyloid in Vivo
Yang, F., Lim, G. P., Begum, A. N., Ubeda, O. J., Simmons, M. R., Ambegaokar, S. S., Chen, P. P., Kayed, R., Glabe, C. G., Frautschy, S. A., et al. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m404751200 · Cited by 2,336
The toxic Aβ oligomer and Alzheimer's disease: an emperor in need of clothes
Benilova, I., Karran, E., & De Strooper, B. (2012) · Nature Neuroscience · doi:10.1038/nn.3028 · Cited by 1,962
High-Level Neuronal Expression of Aβ1–42in Wild-Type Human Amyloid Protein Precursor Transgenic Mice: Synaptotoxicity without Plaque Formation
Mucke, L., Masliah, E., Yu, G.-Q., Mallory, M., Rockenstein, E. M., Tatsuno, G., Hu, K., Kholodenko, D., Johnson-Wood, K., & McConlogue, L. (2000) · The Journal of Neuroscience · doi:10.1523/jneurosci.20-11-04050.2000 · Cited by 1,856

Flagged first, then by citations

Show all 198 references

Research works printed but not linked: 1

Nigh AB, Vahedi S, Davis EG, Weintraub S, Bigio EH, Klein WL, Geula C (2014) Intracellular Amyloid-beta in cholinergic neurons. Brain J Neurol: In Press

Sorted by citations

Items 101–200 of 635

Aβ42 pentamers/hexamers are the smallest detectable oligomers in solution
Wolff, M., Zhang-Haagen, B., Decker, C., Barz, B., Schneider, M., Biehl, R., Rădulescu, A., Strodel, B., Willbold, D., & Nagel‐Steger, L. (2017) · Scientific Reports · doi:10.1038/s41598-017-02370-3 · Cited by 58
The Full Spectrum of Alzheimer’s Disease Is Rooted in Metabolic Derangements That Drive Type 3 Diabetes
de la Monte, S. M. (2019) · Advances in experimental medicine and biology · doi:10.1007/978-981-13-3540-2_4 · Cited by 59
Biosensors on the road to early diagnostic and surveillance of Alzheimer's disease
Carneiro, P., Morais, S., & Pereira, M. D. C. (2020) · Talanta · doi:10.1016/j.talanta.2019.120700 · Cited by 59
Amyloid-β oligomers are captured by the DNAJB6 chaperone: Direct detection of interactions that can prevent primary nucleation
Österlund, N., Lundqvist, M., Ilag, L. L., Gräslund, A., & Emanuelsson, C. S. (2020) · Journal of Biological Chemistry · doi:10.1074/jbc.ra120.013459 · Cited by 57
Alternative processing of the amyloid precursor protein family by rhomboid protease RHBDL4.
Paschkowsky, S., Hamzé, M., Oestereich, F., & Munter, L. M. (2016) · Journal of Biological Chemistry · doi:10.1074/jbc.m116.753582 · Cited by 58
Detection of Aβ oligomers based on magnetic-field-assisted separation of aptamer-functionalized Fe 3 O 4 magnetic nanoparticles and BaYF 5 :Yb,Er nanoparticles as upconversion fluorescence labels
Jiang, L., Chen, B.-C., Chen, B., Li, X.-J., Liao, H., Huang, H., Guo, Z., Zhang, W., & Wu, L. H. (2017) · Talanta · doi:10.1016/j.talanta.2017.04.021 · Cited by 57
Targeting Apolipoprotein E/Amyloid β Binding by Peptoid CPO_Aβ17-21 P Ameliorates Alzheimer’s Disease Related Pathology and Cognitive Decline
Liu, S., Park, S.-A., Allington, G., Prelli, F., Sun, Y., Martá-Ariza, M., Scholtzova, H., Biswas, G. K., Brown, B., Verghese, P. B., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-08604-8 · Cited by 58
Early-Stage Alzheimer’s Disease Is Associated with Simultaneous Systemic and Central Nervous System Dysregulation of Insulin-Linked Metabolic Pathways
de la Monte, S. M., Tong, M., Daiello, L. A., & Ott, B. R. (2019) · Journal of Alzheimer s Disease · doi:10.3233/jad-180906 · Cited by 63
Targeting CCR3 to Reduce Amyloid-β Production, Tau Hyperphosphorylation, and Synaptic Loss in a Mouse Model of Alzheimer’s Disease
Zhu, C., Xu, B., Sun, X., Zhu, Q., & Sui, Y. (2016) · Molecular Neurobiology · doi:10.1007/s12035-016-0269-5 · Cited by 59
The neurotoxicity of amyloid β-protein oligomers is reversible in a primary neuron model
Tanokashira, D., Mamada, N., Yamamoto, F., Taniguchi, K., Tamaoka, A., Lakshmana, M. K., & Araki, W. (2017) · Molecular Brain · doi:10.1186/s13041-016-0284-5 · Cited by 59
Chinese Herbal Medicine Interventions in Neurological Disorder Therapeutics by Regulating Glutamate Signaling
Liu, Y., Wang, S., Kan, J., Zhang, J., Zhou, L., Huang, Y., & Zhang, Y. (2019) · Current Neuropharmacology · doi:10.2174/1570159x17666191101125530 · Cited by 56
Intranasal delivery of pro-resolving lipid mediators rescues memory and gamma oscillation impairment in AppNL-G-F/NL-G-F mice
Emre, C., Arroyo-García, L. E., Do, K. V., Jun, B., Ohshima, M., Alcalde, S. G., Cothern, M. L., Maioli, S., Nilsson, P., Hjorth, E., et al. (2022) · Communications Biology · doi:10.1038/s42003-022-03169-3 · Cited by 55
Amyloid fibrils act as a reservoir of soluble oligomers, the main culprits in protein deposition diseases
Bigi, A., Cascella, R., Chiti, F., & Cecchi, C. (2022) · BioEssays · doi:10.1002/bies.202200086 · Cited by 56
Sunitinib, a Clinically Used Anticancer Drug, Is a Potent AChE Inhibitor and Attenuates Cognitive Impairments in Mice
Huang, L., Lin, J., Xiang, S., Zhao, K., Yu, J., Zheng, J., Xu, D., Mak, S., Hu, S., Nirasha, S., et al. (2016) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.5b00329 · Cited by 55
Multifunctional Superparamagnetic Iron Oxide Nanoparticles Conjugated with Aβ Oligomer-Specific scFv Antibody and Class A Scavenger Receptor Activator Show Early Diagnostic Potentials for Alzheimer’s Disease
Liu, X.-G., Zhang, L., Lu, S., Liu, D.-Q., Zhang, L.-X., Yu, X.-L., & Liu, R.-T. (2020) · International Journal of Nanomedicine · doi:10.2147/ijn.s240953 · Cited by 55
The Role of Lipid Environment in Ganglioside GM1-Induced Amyloid β Aggregation
Rudajev, V., & Novotný, J. (2020) · Membranes · doi:10.3390/membranes10090226 · Cited by 55
Eckmaxol, a Phlorotannin Extracted from Ecklonia maxima , Produces Anti-β-amyloid Oligomer Neuroprotective Effects Possibly via Directly Acting on Glycogen Synthase Kinase 3β
Wang, J., Zheng, J., Huang, C., Zhao, J., Lin, J., Zhou, X., Naman, C. B., Wang, N., Gerwick, W. H., Wang, Q., et al. (2018) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.7b00527 · Cited by 54
Direct Activation of Protein Phosphatase 2A (PP2A) by Tricyclic Sulfonamides Ameliorates Alzheimer's Disease Pathogenesis in Cell and Animal Models
Wei, H., Zhang, H., Wang, X., Xie, J., An, D., Wan, L., Wang, J., Zeng, Y., Shu, X., Westermarck, J. K., et al. (2020) · Neurotherapeutics · doi:10.1007/s13311-020-00841-6 · Cited by 54
Engeletin Attenuates Aβ1–42-Induced Oxidative Stress and Neuroinflammation by Keap1/Nrf2 Pathway
Huang, Z., Ji, H., Shi, J., Zhu, X., & Zhi, Z. (2020) · Inflammation · doi:10.1007/s10753-020-01250-9 · Cited by 54
Benefits in Alzheimer’s Disease of Sensory and Multisensory Stimulation
Yang, H., Luo, Y., Hu, Q., Tian, X., & Wen, H. (2021) · Journal of Alzheimer s Disease · doi:10.3233/jad-201554 · Cited by 54
ACU193: An Immunotherapeutic Poised to Test the Amyloid β Oligomer Hypothesis of Alzheimer’s Disease
Krafft, G. A., Jerecı̀ć, J., Siemers, E., & Cline, E. N. (2022) · Frontiers in Neuroscience · doi:10.3389/fnins.2022.848215 · Cited by 54
Necroptosis and Alzheimer’s Disease: Pathogenic Mechanisms and Therapeutic Opportunities
Zhang, R., Song, Y., & Su, X. (2022) · Journal of Alzheimer s Disease · doi:10.3233/jad-220809 · Cited by 56
Dementia with Lewy Bodies: Molecular Pathology in the Frontal Cortex in Typical and Rapidly Progressive Forms
Garcia‐Esparcia, P., López‐González, I., Grau‐Rivera, O., Garrido, M. G., Koneti, A., Llorens, F., Zafar, S., Carmona, M., del Río, J. A., Zerr, I., et al. (2017) · Frontiers in Neurology · doi:10.3389/fneur.2017.00089 · Cited by 54
Impact of GM1 on Membrane-Mediated Aggregation/Oligomerization of β-Amyloid: Unifying View
Cebecauer, M., Hof, M., & Amaro, M. (2017) · Biophysical Journal · doi:10.1016/j.bpj.2017.03.009 · Cited by 51
Reduced expression of SIRT1 and SOD-1 and the correlation between these levels in various regions of the brains of patients with Alzheimer's disease
Cao, K., Dong, Y., Xiang, J., Xu, Y., Hong, W., Song, H., & Guan, Z.-Z. (2018) · Journal of Clinical Pathology · doi:10.1136/jclinpath-2018-205320 · Cited by 53
Engineering three-dimensional microenvironments towards in vitro disease models of the central nervous system
Yildirimer, L., Zhang, Q., Kuang, S., Cheung, J. C., Chu, K. A., He, Y., Yang, M., & Zhao, X. (2019) · Biofabrication · doi:10.1088/1758-5090/ab17aa · Cited by 54
VEGF counteracts amyloid-β-induced synaptic dysfunction
Martin, L., Bouvet, P., Chounlamountri, N., Watrin, C., Besançon, R., Pinatel, D., Meyronet, D., Honnorat, J., Buisson, A., Salin, P. A., et al. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.109121 · Cited by 52
Amyloid-β oligomers interact with NMDA receptors containing GluN2B subunits and metabotropic glutamate receptor 1 in primary cortical neurons: Relevance to the synapse pathology of Alzheimer’s disease
Taniguchi, K., Yamamoto, F., Amano, A., Tamaoka, A., Sanjo, N., Yokota, T., Kametani, F., & Araki, W. (2022) · Neuroscience Research · doi:10.1016/j.neures.2022.03.001 · Cited by 57
Versatile fluorescent probes for near-infrared imaging of amyloid-β species in Alzheimer's disease mouse model
Peng, C., Wang, X., Li, Y., Li, H., & Wong, M. S. (2019) · Journal of Materials Chemistry B · doi:10.1039/c9tb00161a · Cited by 51
BACE1 SUMOylation increases its stability and escalates the protease activity in Alzheimer’s disease
Bao, J., Qin, M., Mahaman, Y. A. R., Zhang, B., Huang, F., Zeng, K., Xia, Y., Ke, D., Wang, Q., Liu, R., et al. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1800498115 · Cited by 50
Anthoxanthin Polyphenols Attenuate Aβ Oligomer‐induced Neuronal Responses Associated with Alzheimer's Disease
Pate, K. M., Rogers, M., Reed, J. W., van der Munnik, N. P., Vance, S. Z., & Moss, M. A. (2016) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.12659 · Cited by 51
Brain Inflammation Connects Cognitive and Non-Cognitive Symptoms in Alzheimer’s Disease
Sellés, M. C., Oliveira, M. M., & Ferreira, S. T. (2018) · Journal of Alzheimer s Disease · doi:10.3233/jad-179925 · Cited by 51
Observation of β-Amyloid Peptide Oligomerization by Pressure-Jump NMR Spectroscopy
Barnes, C. A., Robertson, A. J., Louis, J. M., Anfinrud, P., & Bax, A. (2019) · Journal of the American Chemical Society · doi:10.1021/jacs.9b06970 · Cited by 50
New Evidence for P-gp-Mediated Export of Amyloid-β Peptides in Molecular, Blood-Brain Barrier and Neuronal Models
Chai, A. B., Hartz, A. M. S., Gao, X., Yang, A., Callaghan, R., & Gelissen, I. C. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms22010246 · Cited by 51
Using near-infrared enhanced thermozyme and scFv dual-conjugated Au nanorods for detection and targeted photothermal treatment of Alzheimer's disease
Liu, D., Li, W., Jiang, X., Bai, S., Liu, J., Liu, X., Shi, Y., Kuai, Z., Kong, W., Gao, R., et al. (2019) · Theranostics · doi:10.7150/thno.30649 · Cited by 49
Nanotechnology for the diagnosis and treatment of Alzheimer's disease: A bibliometric analysis
Li, L., He, R., Yan, H., Leng, Z., Zhu, S., & Gu, Z. (2022) · Nano Today · doi:10.1016/j.nantod.2022.101654 · Cited by 49
Key Peptides and Proteins in Alzheimer’s Disease
Penke, B., Bogár, F., Paragi, G., Gera, J., & Fülöp, L. (2019) · Current Protein and Peptide Science · doi:10.2174/1389203720666190103123434 · Cited by 51
Neonatal infection leads to increased susceptibility to Aβ oligomer-induced brain inflammation, synapse loss and cognitive impairment in mice
Frost, P. S., Barros‐Aragão, F. G. Q., da Silva, R. T., Venancio, A. M., Matias, I. C. P., Silva, N. M. L. E., Kincheski, G. C., Pimentel‐Coelho, P. M., Felice, F. G. D., Gomes, F. C. A., et al. (2019) · Cell Death and Disease · doi:10.1038/s41419-019-1529-x · Cited by 51
A Clinical Trial of Transcranial Electromagnetic Treatment in Alzheimer’s Disease: Cognitive Enhancement and Associated Changes in Cerebrospinal Fluid, Blood, and Brain Imaging
Arendash, G. W., Cao, C., Abulaban, H., Baranowski, R., Wisniewski, G., Becerra, L. R., Andel, R., Lin, X., Zhang, X., Wittwer, D., et al. (2019) · Journal of Alzheimer s Disease · doi:10.3233/jad-190367 · Cited by 52
Interaction of Aβ42 with Membranes Triggers the Self-Assembly into Oligomers
Banerjee, S., Hashemi, M., Zagorski, K., & Lyubchenko, Y. L. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21031129 · Cited by 51
Molecular Mechanism of Vitamin K2 Protection against Amyloid-β-Induced Cytotoxicity
Huang, S.-H., Fang, S.-T., & Chen, Y.-C. (2021) · Biomolecules · doi:10.3390/biom11030423 · Cited by 49
Electrochemical Immunosensors Developed for Amyloid-Beta and Tau Proteins, Leading Biomarkers of Alzheimer’s Disease
Sharma, A., Angnes, L., Sattarahmady, N., Negahdary, M., & Heli, H. (2023) · Biosensors · doi:10.3390/bios13070742 · Cited by 48
Regulation of glycolysis-derived L-lactate production in astrocytes rescues the memory deficits and Aβ burden in early Alzheimer’s disease models
Yang, X., Chen, Y.-H., Liu, L., Gu, Z., You, Y., Hao, J., Sun, N., & Gao, C. (2024) · Pharmacological Research · doi:10.1016/j.phrs.2024.107357 · Cited by 49
Opportunities and challenges in developing relevant animal models for Alzheimer’s disease
Felice, F. G. D., & Munoz, D. P. (2016) · Ageing Research Reviews · doi:10.1016/j.arr.2016.01.006 · Cited by 50
Identification of intraneuronal amyloid beta oligomers in locus coeruleus neurons of Alzheimer’s patients and their potential impact on inhibitory neurotransmitter receptors and neuronal excitability
Kelly, L., Seifi, M., Ma, R., Mitchell, S. J., Rudolph, U., Viola, K. L., Klein, W. L., Lambert, J. J., & Swinny, J. D. (2020) · Neuropathology and Applied Neurobiology · doi:10.1111/nan.12674 · Cited by 48
Self-citation
Role of Intracellular Amyloid β as Pathway Modulator, Biomarker, and Therapy Target
Villarejo, L. G., Bachmann, L., Marks, D., Brachthäuser, M., Geidies, A., & Müller, T. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23094656 · Cited by 48
C3N nanodots inhibits Aβ peptides aggregation pathogenic path in Alzheimer’s disease
Yin, X., Zhou, H., Zhang, M., Su, J., Wang, X. L., Li, S., Yang, Z., Kang, Z., & Zhou, R. (2023) · Nature Communications · doi:10.1038/s41467-023-41489-y · Cited by 50
Bone-Marrow-Derived Microglia-Like Cells Ameliorate Brain Amyloid Pathology and Cognitive Impairment in a Mouse Model of Alzheimer’s Disease
Kawanishi, S., Takata, K., Itezono, S., Nagayama, H., Konoya, S., Chisaki, Y., Toda, Y., Nakata, S., Yano, Y., Kitamura, Y., et al. (2018) · Journal of Alzheimer s Disease · doi:10.3233/jad-170994 · Cited by 47
Transition metal complexes as imaging or therapeutic agents for neurodegenerative diseases
Ma, D., Wu, C., Li, G., Yung, T.-L., & Leung, C. (2020) · Journal of Materials Chemistry B · doi:10.1039/c9tb02669j · Cited by 47
Oral Treponema denticola Infection Induces Aβ1–40 and Aβ1–42 Accumulation in the Hippocampus of C57BL/6 Mice
Su, X., Tang, Z., Lu, Z.-Y., Liu, Y., He, W., Jiang, J., Zhang, Y., & Wu, H. (2021) · Journal of Molecular Neuroscience · doi:10.1007/s12031-021-01827-5 · Cited by 47
Linking in domain-swapped protein dimers
Baiesi, M., Orlandini, E., Trovato, A., & Seno, F. (2016) · Scientific Reports · doi:10.1038/srep33872 · Cited by 46
Stress-Induced Synaptic Dysfunction and Neurotransmitter Release in Alzheimer’s Disease: Can Neurotransmitters and Neuromodulators be Potential Therapeutic Targets?
Jha, S. K., Jha, N. K., Kumar, D., Sharma, R., Shrivastava, A., Ambasta, R. K., & Kumar, P. (2016) · Journal of Alzheimer s Disease · doi:10.3233/jad-160623 · Cited by 48
Association of Neuropathological Markers in the Parietal Cortex With Antemortem Cognitive Function in Persons With Mild Cognitive Impairment and Alzheimer Disease
Tremblay, C., François, A., Delay, C., Freland, L., Vandal, M., Bennett, D. A., & Calon, F. (2017) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/nlw109 · Cited by 49
Proteolytic shedding of the prion protein via activation of metallopeptidase ADAM10 reduces cellular binding and toxicity of amyloid-β oligomers
Jarosz-Griffiths, H., Corbett, N. J., Rowland, H. A., Fisher, K., Jones, A. C., Baron, J., Howell, G. J., Cowley, S. A., Chintawar, S., Cader, M. Z., et al. (2019) · Journal of Biological Chemistry · doi:10.1074/jbc.ra118.005364 · Cited by 45
Discovery of Investigational Drug CT1812, an Antagonist of the Sigma-2 Receptor Complex for Alzheimer’s Disease
Rishton, G. M., Look, G. C., Ni, Z., Zhang, J. Y., Wang, Y., Huang, Y., Wu, X., Izzo, N. J., Mozzoni, K., Limegrover, C. S., et al. (2021) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.1c00048 · Cited by 45
Recent advancements toward therapeutic vaccines against Alzheimer’s disease
Herline, K., Drummond, E., & Wısnıewskı, T. (2018) · Expert Review of Vaccines · doi:10.1080/14760584.2018.1500905 · Cited by 46
Toxic amyloid-β oligomers induced self-replication in astrocytes triggering neuronal injury
Wang, W., Hou, T., Jia, L.-F., Wu, Q., Quan, M., & Jia, J. (2019) · EBioMedicine · doi:10.1016/j.ebiom.2019.03.049 · Cited by 42
Emerging roles of N- and C-terminally truncated Aβ species in Alzheimer’s disease
Wirths, O., & Zampar, S. (2019) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2019.1702972 · Cited by 44
Neuroprotective Effects of Palmatine via the Enhancement of Antioxidant Defense and Small Heat Shock Protein Expression in Aβ‐Transgenic Caenorhabditis elegans
Jia, W., Su, Q., Cheng, Q., Peng, Q., Qiao, A., Luo, X., Zhang, J., & Wang, Y. (2021) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2021/9966223 · Cited by 45
Neuropathology of the Alzheimer's continuum: an update
Jellinger, K. A. (2020) · Free Neuropathology · doi:10.17879/freeneuropathology-2020-3050 · Cited by 52
Inhibiting Aβ toxicity in Alzheimer's disease by a pyridine amine derivative
Zhu, Z., Yang, T., Zhang, L., Liu, L., Yin, E., Zhang, C., Guo, Z., Chen, X., & Wang, X. (2019) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2019.02.052 · Cited by 44
Telmisartan ameliorates Aβ oligomer-induced inflammation via PPARγ/PTEN pathway in BV2 microglial cells
Wang, X., Li, J., Ma, C., Huang, C., & Li, Z. (2019) · Biochemical Pharmacology · doi:10.1016/j.bcp.2019.113674 · Cited by 45
Detection of retinal and blood Aβ oligomers with nanobodies
Habiba, U., Descallar, J., Kreilaus, F., Adhikari, U. K., Kumar, S., Morley, J. W., Bui, B. V., Koronyo‐Hamaoui, M., & Tayebi, M. (2021) · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · doi:10.1002/dad2.12193 · Cited by 43
Electroacupuncture Improves Memory and Protects Neurons by Regulation of the Autophagy Pathway in a Rat Model of Alzheimer—s Disease
Guo, H.-D., Zhu, J., Tian, J.-X., Shao, S.-J., Xu, Y., Mou, F.-F., Han, X.-J., Yu, Z., Chen, J., Zhang, D., et al. (2016) · Acupuncture in Medicine · doi:10.1136/acupmed-2015-010894 · Cited by 42
Expression levels of the α7 nicotinic acetylcholine receptor in the brains of patients with Alzheimer's disease and their effect on synaptic proteins in SH-SY5Y cells
Ren, J.-M., Zhang, S.-L., Wang, X., Guan, Z., & Qi, X. (2020) · Molecular Medicine Reports · doi:10.3892/mmr.2020.11253 · Cited by 43
β-Amyloid fibrils catalyze neurotransmitter degradation
Arad, E., Leshem, A. B., Rapaport, H., & Jelinek, R. (2021) · Chem Catalysis · doi:10.1016/j.checat.2021.07.005 · Cited by 42
Intranasal rifampicin for Alzheimer's disease prevention
Umeda, T., Tanaka, A., Sakai, A., Yamamoto, A., Sakane, T., & Tomiyama, T. (2018) · Alzheimer s & Dementia Translational Research & Clinical Interventions · doi:10.1016/j.trci.2018.06.012 · Cited by 40
Alzheimer’s disease pathological lesions activate the spleen tyrosine kinase
Schweig, J. E., Yao, H., Beaulieu‐Abdelahad, D., Ait‐Ghezala, G., Mouzon, B., Crawford, F., MULLAN, M. J., & Paris, D. (2017) · Acta Neuropathologica Communications · doi:10.1186/s40478-017-0472-2 · Cited by 40
Adenovirus-Mediated Transduction of Insulin-Like Growth Factor 1 Protects Hippocampal Neurons from the Toxicity of Aβ Oligomers and Prevents Memory Loss in an Alzheimer Mouse Model
Sellés, M. C., Fortuna, J. T. S., Zappa-Villar, M. F., de Faria, Y. P. R., de Souza, A. S., Suemoto, C. K., Leite, R. E. P., Rodriguez, R. D., Grinberg, L. T., Reggiani, P. C., et al. (2019) · Molecular Neurobiology · doi:10.1007/s12035-019-01827-y · Cited by 42
A review on α-mangostin as a potential multi-target-directed ligand for Alzheimer's disease
Yang, A., Liu, C., Wu, J., Kou, X., & Shen, R. (2021) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2021.173950 · Cited by 41
Metformin a Potential Pharmacological Strategy in Late Onset Alzheimer’s Disease Treatment
Poor, S. R., Ettcheto, M., Cano, A. C., Sánchez‐López, E., Manzine, P. R., Olloquequi, J., Camins, A., & Javan, M. (2021) · Pharmaceuticals · doi:10.3390/ph14090890 · Cited by 41
Synthetic amyloid-β oligomers drive early pathological progression of Alzheimer’s disease in nonhuman primates
Yue, F., Feng, S., Lu, C., Zhang, T., Tao, G., Liu, J., Yue, C., & Jing, N. (2021) · iScience · doi:10.1016/j.isci.2021.103207 · Cited by 41
Exploration of Aberrant E3 Ligases Implicated in Alzheimer’s Disease and Development of Chemical Tools to Modulate Their Function
Potjewyd, F., & Axtman, A. D. (2021) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2021.768655 · Cited by 37
Therapeutic Potential of Targeting Mitochondria for Alzheimer’s Disease Treatment
Atlante, A., Amadoro, G., Latina, V., & Valenti, D. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11226742 · Cited by 40
Oxidative Stress and Natural Antioxidants: Back and Forth in the Neurological Mechanisms of Alzheimer’s Disease
Mani, S., Dubey, R., Lai, I., Babu, M. A., Tyagi, S., Swargiary, G., Mody, D., Singh, M., Agarwal, S., Iqbal, D., et al. (2023) · Journal of Alzheimer s Disease · doi:10.3233/jad-220700 · Cited by 43
Amyloid β-protein oligomers upregulate the β-secretase, BACE1, through a post-translational mechanism involving its altered subcellular distribution in neurons
Mamada, N., Tanokashira, D., Hosaka, A., Kametani, F., Tamaoka, A., & Araki, W. (2015) · Molecular Brain · doi:10.1186/s13041-015-0163-5 · Cited by 40
Otophylloside B Protects Against Aβ Toxicity in Caenorhabditis elegans Models of Alzheimer’s Disease
Yang, J., Huang, X., Wan, Q.-L., Ding, A.-J., Yang, Z., Qiu, M., Sun, H., Qi, S., & Luo, H. (2017) · Natural Products and Bioprospecting · doi:10.1007/s13659-017-0122-1 · Cited by 41
Dexibuprofen prevents neurodegeneration and cognitive decline in APPswe/PS1dE9 through multiple signaling pathways
Ettcheto, M., Sánchez‐López, E., Pons, L., Busquets, O., Olloquequi, J., Beas‐Zárate, C., Pallàs, M., García, M. L., Auladell, C., Folch, J., et al. (2017) · Redox Biology · doi:10.1016/j.redox.2017.06.003 · Cited by 39
Amyloid β-peptides 1–40 and 1–42 form oligomers with mixed β-sheets
Baldassarre, M., Baronio, C. M., Morozova‐Roche, L. A., & Barth, A. (2017) · Chemical Science · doi:10.1039/c7sc01743j · Cited by 39
Design and Synthesis of Novel Hybrid 8-Hydroxy Quinoline-Indole Derivatives as Inhibitors of Aβ Self-Aggregation and Metal Chelation-Induced Aβ Aggregation
Bowroju, S. K., Mainali, N., Ayyadevara, S., Penthala, N. R., Krishnamachari, S., Kakraba, S., Reis, R. J. S., & Crooks, P. A. (2020) · Molecules · doi:10.3390/molecules25163610 · Cited by 37
APOE ε4/ε4 homozygotes with early Alzheimer's disease show accelerated hippocampal atrophy and cortical thinning that correlates with cognitive decline
Abushakra, S. R., Porsteinsson, A. P., Sabbagh, M. N., Bracoud, L., Schaerer, J., Power, A., Hey, J. A., Scott, D., Suhy, J., Tolar, M., et al. (2020) · Alzheimer s & Dementia Translational Research & Clinical Interventions · doi:10.1002/trc2.12117 · Cited by 40
Docosahexaenoic acid enhances hippocampal insulin sensitivity to promote cognitive function of aged rats on a high-fat diet
Xu, J., Ni, B., Ma, C., Rong, S., Gao, H. Y., Zhang, L., Xia, X., Huang, Q., Deng, Q., & Huang, F. (2022) · Journal of Advanced Research · doi:10.1016/j.jare.2022.04.015 · Cited by 39
Is Stroke a Neurodegenerative Condition? A Critical Review of Secondary Neurodegeneration and Amyloid-beta Accumulation after Stroke
Ong, L. K., Walker, F. R., & Nilsson, M. (2017) · AIMS Medical Science · doi:10.3934/medsci.2017.1.1 · Cited by 37
A small molecule Nec-1 directly induces amyloid clearance in the brains of aged APP/PS1 mice
Yang, S., Shin, J., Shin, N. N., Hwang, J., Hong, S.-C., Park, K., Lee, J. W., Lee, S., Baek, S., Kim, K., et al. (2019) · Scientific Reports · doi:10.1038/s41598-019-40205-5 · Cited by 38
Endosomal dysfunction impacts extracellular vesicle release: Central role in Aβ pathology
Arbo, B. D., Cechinel, L. R., Palazzo, R. P., & Siqueira, I. R. (2019) · Ageing Research Reviews · doi:10.1016/j.arr.2019.101006 · Cited by 40
Insulin Resistance as a Common Link Between Current Alzheimer’s Disease Hypotheses
Alves, S. S., da Silva-Júnior, R. M. P., Servilha‐Menezes, G., Homolak, J., Šalković‐Petrišić, M., & Garcia‐Cairasco, N. (2021) · Journal of Alzheimer s Disease · doi:10.3233/jad-210234 · Cited by 39
Apolipoprotein E isoform-dependent effects on the processing of Alzheimer's amyloid-β
Chai, A. B., Lam, H. H. J., Kockx, M., & Gelissen, I. C. (2021) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2021.158980 · Cited by 41
NMDA receptor antagonists reduce amyloid-β deposition by modulating calpain-1 signaling and autophagy, rescuing cognitive impairment in 5XFAD mice
Companys‐Alemany, J., Turcu, A. L., Schneider, M., Müller, C. E., Vázquez, S., Griñán‐Ferré, C., & Pallàs, M. (2022) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-022-04438-4 · Cited by 43
Unprecedented polycyclic polyprenylated acylphloroglucinols with anti-Alzheimer's activity from St. John's wort
Guo, Y., Huang, F., Sun, W., Zhou, Y., Chen, C., Qi, C., Yang, J., Li, X.-N., Luo, Z., Zhu, H., et al. (2021) · Chemical Science · doi:10.1039/d1sc03356e · Cited by 37
Design, synthesis, and evaluation of a water soluble C5-monoketone type curcumin analogue as a potent amyloid β aggregation inhibitor
Hotsumi, M., Tajiri, M., Nikaido, Y., Sato, T., Makabe, K., & Konno, H. (2019) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2019.06.052 · Cited by 36
Annexin A5 prevents amyloid-β-induced toxicity in choroid plexus: implication for Alzheimer’s disease
Bartolomé, F. B., Krzyzanowska, A., de la Cueva, M., Pascual, C., Antequera, D., Spuch, C., Villarejo‐Galende, A., Rábano, A., Fortea, J., Alcolea, D. A., et al. (2020) · Scientific Reports · doi:10.1038/s41598-020-66177-5 · Cited by 35
Genetic variants for personalised management of very low carbohydrate ketogenic diets
Aronica, L., Volek, J. S., Poff, A. M., & D’Agostino, D. P. (2020) · BMJ Nutrition Prevention & Health · doi:10.1136/bmjnph-2020-000167 · Cited by 37
Axonal Transport and Local Translation of mRNA in Neurodegenerative Diseases
Nagano, S., & Araki, T. (2021) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2021.697973 · Cited by 36
Intrinsically disordered proteins in various hypotheses on the pathogenesis of Alzheimer's and Parkinson's diseases
Coskuner‐Weber, O., & Uversky, V. N. (2019) · Progress in molecular biology and translational science · doi:10.1016/bs.pmbts.2019.05.007 · Cited by 35
Nanopolyphenol rejuvenates microglial surveillance of multiple misfolded proteins through metabolic reprogramming
Wang, D., Gu, X. Q., Ma, X., Chen, J., Zhang, Q., Yu, Z., Li, J., Meng, H., Tan, X., Tang, Y., et al. (2022) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2022.07.014 · Cited by 35
Multifunctional Liposomes Targeting Amyloid‐β Oligomers for Early Diagnosis and Therapy of Alzheimer's Disease
Senapati, S., Tripathi, K. K., Awad, K., & Rahimipour, S. (2024) · Small · doi:10.1002/smll.202311670 · Cited by 39
Gold Nanoparticle-Decorated Catalytic Micromotor-Based Aptassay for Rapid Electrochemical Label-Free Amyloid-β42 Oligomer Determination in Clinical Samples from Alzheimer’s Patients
Gallo-Orive, Á., Moreno‐Guzmán, M., Sánchez-Paniagua, M., Montero‐Calle, A., Barderas, R., & Escarpa, A. (2024) · Analytical Chemistry · doi:10.1021/acs.analchem.3c05665 · Cited by 35
Neuronal tetraploidization in the cerebral cortex correlates with reduced cognition in mice and precedes and recapitulates Alzheimer's-associated neuropathology
López‐Sánchez, N., Fontán‐Lozano, Á., Pallé, A., González-Álvarez, V., Rábano, A., Trejo, J. L., & Frade, J. M. (2017) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2017.04.008 · Cited by 33
A human scFv antibody that targets and neutralizes high molecular weight pathogenic amyloid‐β oligomers
Sebollela, A. S., Cline, E. N., Popova, I. A., Luo, K., Sun, X., Ahn, J., Barcelos, M. A., Bezerra, V. N., Silva, N. M. L. E., Patel, J., et al. (2017) · Journal of Neurochemistry · doi:10.1111/jnc.14118 · Cited by 38
Self-citation
A Novel Selective PKR Inhibitor Restores Cognitive Deficits and Neurodegeneration in Alzheimer Disease Experimental Models
Lopez‐Grancha, M., Bernardelli, P., Moindrot, N., Genet, E., Vincent, C., Roudières, V., Krick, A., Sabuco, J.-F., Machnik, D., Ibghi, D., et al. (2021) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.121.000590 · Cited by 34

Authors: Viola, K. L., & Klein, W. L.
Affiliations: Northwestern University (US)
Corresponding author: Klein, William L.
ORCID: Viola, Kirsten L.
Klein, William L.
Venue: Acta Neuropathologica
Publisher: Springer Science and Business Media LLC
Published: 2015-01-22
Volume: 129
Issue: 2
Pages: 183-206
ISSN: 0001-6322 (ISSN-L)
1432-0533
DOI: 10.1007/s00401-015-1386-3
PMC: PMC4390393
OpenAlex: W2055775253
Cited by: 628
References: 198
Citations by year: 2026: 42 · 2025: 45 · 2024: 55 · 2023: 51 · 2022: 75 · 2021: 69 · 2020: 66 · 2019: 58 · 2018: 60 · 2017: 53 · 2016: 42 · 2015: 10
FWCI: 6.76
Type: journal article
Language: en
Open access: green
www.ncbi.nlm.nih.gov
Licence: www.springer.com/tdm (tdm)
Locations: Acta Neuropathologica (publishedVersion)
PubMed (publishedVersion)
PubMed Central (acceptedVersion)
Funders: National Institutes of Health
National Institute on Aging (AG045637, AG029460, R01AG022547, AG022547, R01AG029460, R21AG045637)
Topics: Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
Keywords: amyloid-beta oligomers, Alzheimer's disease pathogenesis, protein aggregation, neurotoxicity, synaptic dysfunction, glutamate receptors, calcium overload, tau hyperphosphorylation, insulin resistance, oxidative stress, synaptic loss, cerebrospinal fluid biomarkers, diabetes comorbidity, hypercholesterolemia, Alzheimer's disease therapeutics
MeSH terms: Alzheimer Disease, Animals, Humans, Neurons, Amyloid beta-Peptides

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Amyloid β oligomers in Alzheimer’s disease pathogenesis, treatment, and diagnosis

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks